Skip to main content

Storage & Overactive Bladder Pharmacotherapy

Pharmacologic therapy for overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (NLUTD) works through two complementary mechanisms at the detrusor: blocking cholinergic contraction (antimuscarinics) or stimulating sympathetic relaxation (β3-agonists). A third distinct agent, desmopressin, addresses nocturnal polyuria rather than storage per se.

This subcategory covers the two oral drug classes for storage symptoms, desmopressin for nocturnal polyuria, and intradetrusor botulinum toxin. For the full clinical framework see the AUA/SUFU OAB guideline, the OAB clinical-condition article and the Nocturia article.

Contemporary Treatment Selection (AUA/SUFU 2024)​

For idiopathic OAB, the 2024 AUA/SUFU guideline recommends bladder training and other behavioral therapies ; further treatment is chosen through shared decision-making .[4] Offer an antimuscarinic or a β3-agonist for urgency, frequency and urgency incontinence ; counsel on each class's adverse effects and discuss possible dementia and cognitive impairment with patients taking or being prescribed an antimuscarinic .[4] If an OAB medication gives inadequate benefit or intolerable side effects, another agent in the same or a different class may be offered ; after inadequate monotherapy, a medication from a different class may be added .[4] After inadequate response or intolerable side effects from medication or behavioral therapy, offer sacral neuromodulation, tibial nerve stimulation or intradetrusor onabotulinumtoxinA .[4] The guideline also allows these procedures through shared decision-making without requiring prior behavioral or drug trials [4]; the US BOTOX label indicates onabotulinumtoxinA for adults with OAB symptoms of urge urinary incontinence, urgency and frequency who have had an inadequate response to or are intolerant of an anticholinergic medication.[1] Measure post-void residual before botulinum toxin injection, and repeat it if symptoms worsen or fail to improve afterward. Discuss catheterization and UTI risk and treatment burden when choosing among options. See the AUA/SUFU guideline.

The EAU 2026 non-neurogenic female LUTS guideline is broadly concordant.[3] It offers β3-agonists to women who fail conservative management , uses long-term anticholinergics with caution in older women and those at risk of cognitive dysfunction , and offers 100 U onabotulinumtoxinA for OAB/UUI refractory to conservative therapy or drug treatment after counseling on limited duration, UTI and possible intermittent catheterization . It also offers desmopressin for nocturia due to nocturnal polyuria in women , recommends careful serum sodium monitoring in older recipients , and advises against prescribing it when baseline serum sodium is below the normal range .

For neurogenic OAB symptoms, the EAU 2026 Neuro-Urology guideline recommends antimuscarinics or β3-agonists .[2] For urodynamically proven neurogenic detrusor overactivity, it recommends against β3-agonists to reduce overactivity and recommends detrusor botulinum toxin A when antimuscarinic therapy is ineffective .[2]

Procedural detail is on the Intradetrusor Botox Injection page.

References​

1. BOTOX (onabotulinumtoxinA). US prescribing information. Revised February 2026. DailyMed.

2. European Association of Urology. EAU Guidelines on Neuro-Urology: Limited Update March 2026. 2026. Full guideline.

3. European Association of Urology. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms: Limited Update March 2026. 2026. Full guideline.

4. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11–20. doi:10.1097/JU.0000000000003985